Omeros received $240 million upfront, with total deal value reaching up to $2.1 billion. ・The company retired its senior loan ...

Novo Nordisk in 2020 launched pivotal trials of its GLP-1 drug semaglutide in Alzheimer's patients based on studies in humans ...

Novo Nordisk A/S acquires Zaltenibart for $2.1B, targeting rare diseases. NVO shares present a de-risked entry point. Click for this updated look at NVO stock.

But perhaps the larger story associated with the unsurprising result is the market reaction, as Novo's shares fell by nearly 9% at the U.S. market open Monday.

Wondering if Novo Nordisk is overhyped or a hidden bargain? If you have ever considered whether its current share price stacks up to its true value, you are in the right place. After an impressive 58.

Today, Novo Nordisk announced the submission of a sNDA to the U.S. Food and Drug Administration (FDA) for a higher dose of ...

Novo Nordisk is using its ticket for an extra-speedy regulatory review granted through the FDA’s Commissioner’s National ...

Novo Nordisk's amycretin cut A1C and body weight in a phase 2 study, with no plateau seen, as the company targets a 2026 ...

An older oral version of the company's semaglutide drug failed to meet its main goal in late-stage trials testing whether the ...

Dec 2 () - Wegovy maker Novo Nordisk is planning ​to test its experimental obesity drug, ‌CagriSema, in overweight children ...

Novo Nordisk is by far the leader in the GLP-1 drug market. The company's pipeline in this area is also very deep. The Danish drugmaker is also looking to diversify its lineup. Novo Nordisk's work in ...